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1. Successful clinical implementation of stem cell gene therapy for Pompe’s disease paves the 
way for a variety of other inherited diseases (this thesis); 
 
2. Preclinical evaluation in mice of stem cell based gene therapy as a single intervention 
strategy for Pompe’s disease confirms the high enzyme levels required for optimal efficacy 
of enzyme replacement therapy in patients  (this thesis); 
 
3. Stem cell based gene therapy is unique in clearing glycogen storage in all organs, including 
the brain (this thesis); 
 
4. The current licensing process for gene therapy products is too complicated to be of direct 
benefit to patients (Mavilio, Nature 2012; 490, 7; this thesis); 
 
5. As a single intervention, stem cell based gene therapy for Pompe’s disease is cost-effective 
as an alternative to the current perpetual enzyme replacement therapy; 
 
6. Gene editing of disease-related single mutations will replace the retroviral integration 
strategy for some monogenic disorders in the future; 
 
7. The financial crisis does not only affect scientific research in terms of funding, but it also 
affects the proper education of the general public; 
 
8. It is remarkable that delicious food such as mussels also provides a life-saving tissue glue 
(In: Haller et al., Acta Biomaterials 2012; 8(12):4365-70); 
 
9. The occurrence of totipotent cells observed after in vivo reprogramming might open new 
avenues for regenerative medicine (In: M. Abad et al., Nature. 2013 Sep 11. doi: 
10.1038/nature12586); 
 
10. Stem cell based gene therapy treated Pompe mice are able to “run from Rotterdam to Paris 
in 28 days” (this thesis); 
 
11. Life is not like water. Things in life don’t necessarily flow over the shortest possible route 
(In: H. Murakami, 1Q84, 2009).  
 
